Volume effects of radiotherapy on the risk of second primary cancers: A systematic review of clinical and epidemiological studies

• Published in: Radiotherapy and oncology 2019-02, Vol.131, p.150-159
• Main Authors: Journy, Neige, Mansouri, Imène, Allodji, Rodrigue S., Demoor-Goldschmidt, Charlotte, Ghazi, Debiche, Haddy, Nadia, Rubino, Carole, Veres, Cristina, Zrafi, Wael Salem, Rivera, Sofia, Diallo, Ibrahima, De Vathaire, Florent
• Format: Article
• Language: English
• Subjects: Dose-Response Relationship, Radiation; Hodgkin Disease - radiotherapy; Humans; Incidence; Life Sciences; Neoplasms - radiotherapy; Neoplasms, radiation-induced; Neoplasms, Second Primary - epidemiology; Neoplasms, Second Primary - etiology; Observational Studies as Topic; Radiation dosage; Radiotherapy; Radiotherapy - adverse effects; Radiotherapy - statistics & numerical data; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted - methods; Randomized Controlled Trials as Topic; Review; Risk
• ISSN: 0167-8140; 1879-0887
• DOI: 10.1016/j.radonc.2018.09.017

•SPC risks increased with extended fields for Hodgkin lymphoma or childhood cancers.•No included studies estimated normal tissue dose–volume distribution.•Current clinical evidence on possible volume effects on SPC risks is very limited.•Biological mechanisms underlying volume effects on SPC risks are plausible. As modern radiotherapy, including intensity-modulated techniques, is associated with high dose gradients to normal tissues and large low-to-moderate dose volumes, the assessment of second primary cancer (SPC) risks requires quantification of dose–volume effects. We conducted a systematic review of clinical and epidemiological studies investigating the effect of the irradiated volume or dose–volume distribution to the remaining volume at risk (RVR) on SPC incidence. We identified eighteen studies comparing SPC risks according to the irradiated volume (i.e., in most studies, the size or number of fields used), and four studies reporting risk estimates according to the dose distribution to the RVR (after whole-body dose reconstruction). An increased risk of SPCs (mainly breast and lung cancers) with extended radiotherapy was observed among patients treated for Hodgkin lymphoma or childhood cancers. However, normal tissue dose distribution was not estimated, limiting the interpretation of those results in terms of volume effects on organs at risk. Studies considering whole-body exposures quantified dose–response relationships for point dose estimates, without accounting for dose–volume distributions. Therefore, they disregarded possible tissue effects (e.g. bystander and abscopal effects, stem cell repopulation) which may play a role in the induction of SPCs. Currently, there is no clinical or epidemiological information about a possible role of high dose gradients in surrounding organs, or increasing volumes of distant tissues exposed to low doses, in the risk of SPCs. Opportunities for future research nevertheless now exist, since methods and tools for estimating individual whole-body dose–volume distributions in large patient populations have been developed.